

1 **Supplementary Information**

2 This file contains **Supplementary Note 1-11** and **Supplementary Figures 1-9** followed by the
3 **Supplementary Note-only References**.

4 The Table of Contents is as follows:

5

6 **Supplementary Note 1-11:**

7

8 **Supplementary Note 1A:** *Characterizing newly defined cis-pQTLs within European and African*
9 *ancestries*

10

11 **Supplementary Note 1B:** *Further details on defining “strict variant-to-gene” (strict V2G)*
12 *cis-pQTLs*

13

14 **Supplementary Note 1C:** *Further details on instrumentable proteins in each cohort*

15

16 **Supplementary Note 2:** *Assessing sample overlap in two-sample MR for UK Biobank GWAS*
17 *outcomes and proteomics cohort*

18

19 **Supplementary Note 3:** *Cohort level description of putatively causal protein-phenotype pairs in*
20 *European and African ancestry*

21

22 **Supplementary Note 4:** *Proteins involved in a multitude of traits and diseases*

23

24 **Supplementary Note 5A:** *Validating cardiovascular related putatively causal protein-phenotype*
25 *pairs from prior studies in European ancestries*

26

27 **Supplementary Note 5B:** *Validating non-cardiovascular disease related putatively causal*
28 *protein-phenotype pairs from prior studies in European ancestries*

29

30 **Supplementary Note 5C:** *Exploratory analyses using ARIC African proteomics cohort to*
31 *assess causal effects on binary cardiovascular and autoimmune-related outcomes in the Million*
32 *Veteran Program*

33

34 **Supplementary Note 5D:** *Additional note on uniquely instrumentable proteins in East Asian*
35 *ancestry and putatively causal protein-phenotype pairs from these proteins*

36

37 **Supplementary Note 6:** *Discordant effects across ancestries for putatively causal protein-*
38 *phenotypes pairs*

39

40 **Supplementary Note 7A:** *Druggability of instrumentable protein-coding genes at the cohort*
41 *level*

42

43 **Supplementary Note 7B:** *Overlap of protein-phenotype pairs stratified by ancestry in the*
44 *druggable genome and DrugBank*

45

46 **Supplementary Note 7C:** *Druggability of protein-phenotype pairs by integrating the druggable*
47 *genome, DrugBank, and Open Targets Platform*

48
49 **Supplementary Note 8:** *Prioritization of targets for CAD and T2D*

50
51 **Supplementary Note 9:** *Detailed description of Kyoto University Nagahama East Asian cohort*

52
53 **Supplementary Note 10:** *Detailed description of PWCoCo and SharePro*

54
55 **Supplementary Note 11:** *STROBE-MR checklist*

56
57

58

59 **Supplementary Figure 1-9:**

60

61 **Supplementary Figure 1.** Within-ancestry *cis*-pQTL effect size concordance.

62

63 **Supplementary Figure 2.** Protein-phenotype network plots for other phenotypes in
64 European ancestry; six phenotype categories)

65

66 **Supplementary Figure 3.** Protein-phenotype pairs with discordant direction across
67 ancestries.

68

69 **Supplementary Figure 4.** The overlap between instrumentable protein-coding genes and
70 the druggable genome from Finan et al.

71

72 **Supplementary Figure 5.** UpSet plot showing the overlap between instrumentable
73 proteins and the druggable genome across three ancestries.

74

75 **Supplementary Figure 6.** UpSet plot showing the overlap between instrumentable
76 proteins and the druggable genome across 7 cohorts.

77

78 **Supplementary Figure 7.** European ancestry druggability heatmaps for 12 disease
79 categories.

80

81 **Supplementary Figure 8.** East Asian ancestry druggability heatmaps for 11 disease
82 categories.

83

84 **Supplementary Figure 9.** Prioritizing proteins for coronary artery disease and type 2
85 diabetes.

86

87

88

89 **Supplementary Note-only References**

90 **Supplementary Note 1-11:**

91

92 **Supplementary Note 1A:** *Characterizing newly defined cis-pQTLs within European and African*
93 *ancestries*

94 To verify that newly defined *cis*-pQTLs were comparable, we assessed the within-ancestry
95 concordance of *cis*-pQTL effect sizes in European (**Supplementary Figure 1a**) and in African
96 ancestries (**Supplementary Figure 1b**). We found high concordance of effects suggesting that
97 within each ancestry, the newly defined *cis*-pQTLs are comparable.

98

99 **Methods:**

100 We assessed the within-ancestry concordance between European ancestry proteomics cohorts
101 by aligning the effect allele of *cis*-pQTLs in each cohort to the minor allele in the UKB 50k
102 reference panel. Similarly, when comparing the within-ancestry concordance between African
103 ancestry proteomics cohorts, we first aligned effect alleles of *cis*-pQTLs in each cohort to the
104 minor allele of the corresponding variant in the African ancestry HGDP+1kGP reference panel.

105

106

107 **Supplementary Note 1B:** *Further details on defining “strict variant-to-gene” (strict V2G)*
108 *cis-pQTLs*

109

110 Upon defining *cis*-pQTLs in each cohort, we performed two additional steps to select genetic
111 instruments which we term strict V2G *cis*-pQTLs.

112

113 First, to minimize potential horizontal pleiotropic effects, we removed *cis*-variants associated with
114 two or more protein-coding genes (**Supplementary Note Table 1**), thus retaining *cis*-pQTLs
115 associated with a single protein-coding gene, which we term “strict” *cis*-pQTLs.

116

117 Second, we leveraged multiple sources of evidence to assign variants to genes using Open
118 Targets Genetics V2G score. As expected, upon performing strict V2G filtering within each cohort,
119 we found that strict V2G *cis*-pQTLs had a larger proportion of proteins with a single associated
120 *cis*-pQTL compared to all *cis*-pQTLs (**Supplementary Note Table 2**), and the maximum number
121 of *cis*-pQTLs associated with a single protein was either the same or lower across all cohorts in
122 all ancestries (**Supplementary Note Table 3**). The number of strict V2G *cis*-pQTLs for each
123 protein is shown in **Supplementary Note Table 4**. The maximum number of strict V2G *cis*-pQTLs
124 per protein was larger in all European ancestry cohorts compared to African ancestry cohorts and
125 the Kyoto University Nagahama East Asian ancestry cohort (**Supplementary Note Table 3**). For
126 example, the UKB-PPP European ancestry cohort had a range of 1 up to 21 strict V2G *cis*-pQTLs
127 per protein while the number of strict V2G *cis*-pQTLs per protein in the Kyoto University
128 Nagahama East Asian ancestry cohort ranged from 1 to 3.

129

130

131 **Supplementary Note 1C:** *Further details on instrumentable proteins in each cohort*

132

133 In European ancestries, we identified 1,485 instruments for 1,102 proteins for ARIC ($n = 7,213$;
134 **Supplementary Table 2**), 2,083 instruments for 1,243 proteins for deCODE ($n = 35,559$;
135 **Supplementary Table 3**), 1,637 instruments for 1,194 proteins for Fenland ($n = 10,708$;
136 **Supplementary Table 4**), and 2,194 instruments for 1,292 proteins for UKB-PPP ($n = 34,557$;
137 **Supplementary Table 5**). In African ancestries, we identified 1,080 instruments for 877 proteins
138 for ARIC ($n = 1,871$; **Supplementary Table 6**), and 604 instruments for 554 proteins for UKB-

139 PPP ($n = 931$; **Supplementary Table 7**). Finally, in the Kyoto University Nagahama East Asian
140 ancestry cohort, 663 instruments were identified from 602 proteins ($n = 1,823$; **Supplementary**
141 **Table 8**).

142
143 We also assessed whether any instrumentable proteins were shared across cohorts within
144 European and African ancestries. Here, we use proteins to refer to the protein-coding gene name
145 in order to avoid double counting SomaScan v4 aptamers and to enable harmonization with Olink
146 assays. Protein-coding genes were quantified based on Ensembl gene IDs. Within European
147 ancestries, 434 proteins were shared across all four cohorts while 375 were unique to the ARIC,
148 deCODE, and Fenland cohorts measured with the SomaScan v4 platform, and 652 were unique
149 to the UKB-PPP cohort which measured proteins using Olink Explore 3072 (**Extended Data Fig.**
150 **4a**), highlighting the value of using two proteomics platforms. In African ancestries, 259 proteins
151 were jointly instrumentable by the ARIC and UKB-PPP cohorts while 591 were unique to ARIC
152 and 294 to UKB-PPP (**Extended Data Fig. 4b**) which emphasizes the value of having two cohorts
153 from two separate proteomics platforms. The Kyoto University Nagahama East Asian cohort ($n =$
154 $1,823$) was able to instrument 581 proteins (**Extended Data Fig. 4c**).

155 **Supplementary Note 2: Assessing sample overlap in two-sample MR for UK Biobank GWAS**
156 *outcomes and proteomics cohort*

157
158 To estimate the extent of bias in two-sample MR causal estimates for European exposures that
159 use proteomics GWAS from the UKB-PPP and European GWAS outcomes that were generated
160 from UK Biobank individuals, we calculated relative bias¹ based on the equation:

161
$$Relative\ bias = \phi \times \frac{1}{F}$$

162 The proportion of sample overlap, ϕ , ranges between 0 (no sample overlap) and 1 (complete
163 sample overlap), while the F-statistic of the exposure is denoted by F . Assessments of sample
164 overlap for the European UKB-PPP and African UKB-PPP proteomics cohorts and corresponding
165 UKB outcomes are shown in **Supplementary Note Table 5**.

166
167 Since 51 of 179 European GWAS outcomes were based on the UK Biobank, we estimated the
168 extent of potential bias towards the null due to sample overlap in two-sample MR causal estimates
169 for European exposures that used proteomics GWAS from the UKB-PPP ($n = 34,557$). The
170 relative bias¹ when assuming maximum overlap between proteomics GWAS and the 51 UKB
171 outcome GWAS using the minimum F-statistic of 29.8 was estimated to be between 0.250% and
172 0.769% (**Supplementary Note Table 5**). However, we note that we utilized three additional
173 proteomics cohorts from ARIC, deCODE, and Fenland which may consequently provide further
174 levels of support for these protein-phenotype associations and mitigate this bias.

175 **Supplementary Note 3: Cohort level description of putatively causal protein-phenotype pairs in**
176 **European and African ancestry**

177
178 Our analysis involves two different levels of resolution when describing the results. At the ancestry
179 level, this pertains to European, African, and East Asian ancestries. At the cohort level this
180 involves four cohorts (ARIC, deCODE, Fenland, and UKB-PPP) for European ancestries, two
181 cohorts (ARIC and UKB-PPP) for African ancestries, and the Kyoto University Nagahama cohort
182 for individuals of East Asian ancestry. In the main text, we focus findings at the ancestry level to
183 avoid complicating the results and describe the cohort level details here:

184
185 In European ancestries, we identified a total of 6,771 putatively causal protein-phenotype
186 associations (1,764 pairs in ARIC; 1,731 in deCODE, 1,788 in Fenland, and 1,488 in UKB-PPP)
187 pertaining to 3,949 unique pairs (**Supplementary Table 14** and **Extended Data Fig. 5a**). In
188 African ancestries, we identified a total of 72 associations involving 35 associations in ARIC and
189 37 associations in UKB-PPP, with 56 unique protein-phenotype associations across both cohorts
190 involving 28 proteins and 11 phenotypes (**Supplementary Table 15** and **Extended Data Fig. 5b**).
191 The direction of effect was consistent among all common associations between ARIC and UKB-
192 PPP including well known proteins known to affect HDL cholesterol such as APOC1, CD36,
193 DPEP2, and ITIH4 serving as positive controls.

194
195

196 **Supplementary Note 4: Proteins involved in a multitude of traits and diseases**

197

198 When quantifying the number of associated phenotypes that each protein was associated with,
199 we found pleiotropic proteins associated with up to 49, 5, and 58 unique phenotypes in European,
200 African, and East Asian ancestries, respectively (**Supplementary Note Table 6**). In European
201 ancestries, 13 proteins were putatively causal for 20 or more outcomes including GCKR, GPN1,
202 BTN3A2, SORT1, RSPO3, HP, RAB21, TIMD4, MST1, APOB, EFEMP1, PCSK9, and PLCG1.
203 Since some phenotype categories had a greater number of outcomes than other categories, we
204 quantified the number of associated phenotype categories each protein was implicated in as well
205 (**Supplementary Note Table 7**). These targets present complex scenarios and may have effects
206 in multiple tissues or organs.

207

208 For example, in European ancestries, GCKR (implicated in 10 phenotype categories) increases
209 the risk of type 2 diabetes as previously reported² but our study shows that it also decreases the
210 risk of inflammatory bowel disease (IBD) and cholelithiasis. MST1 (9 phenotype categories) is a
211 macrophage-stimulating protein and hepatocyte growth factor-link protein highly expressed in the
212 liver, suggesting its involvement in immune-related and liver diseases. MST1 has been implicated
213 in IBD³ and its pQTLs have also been found to associate with Crohn's disease, ulcerative colitis,
214 IBD, and primary sclerosing cholangitis (PSC)⁴, a rare liver condition associated with IBD and
215 causing severe liver scarring. We found that increased genetically predicted MST1 levels were
216 protective against IBD, including both Crohn's disease and ulcerative colitis, and PSC. However,
217 despite these protective effects, our results suggest that higher MST1 protein levels may
218 potentially lead to harmful cardiovascular events, such as increased systolic blood pressure and
219 diastolic blood pressure and a higher risk of coronary artery disease.

220

221 In African ancestries, APOA5, APOE, and HP had effects on the most phenotypes with both being
222 associated with 5 outcomes (**Supplementary Note Table 6**). All proteins had effects on
223 phenotypes within a single category aside from ABO and ITIH4 which were causal for outcomes
224 from three and two phenotype categories, respectively (**Supplementary Note Table 7**).

225

226 In East Asian ancestries, ALDH2 was the most pleiotropic protein and putatively causal for 58
227 phenotypes (from 12 phenotype categories) including multiple diseases such as stroke (any
228 ischemic stroke), epilepsy, colorectal cancer, esophageal cancer, hepatic cancer, lung cancer
229 among many others. Notably, ALDH2 was not instrumented in European nor African and was
230 uniquely instrumented in East Asian ancestry. The next most pleiotropic protein in East Asian
231 ancestries was ABO associated with 14 phenotypes (4 phenotype categories) as expected due
232 to known pleiotropy at this locus. MLN, a small peptide hormone secreted by cells in the small
233 intestine which regulates gastrointestinal contractions and motility was causal for 10 phenotypes
234 (6 phenotype categories) including cardiovascular outcomes (angina pectoris and stable angina
235 pectoris), gastrointestinal (chronic hepatitis B), autoimmune (rheumatoid arthritis), cancer (gastric
236 cancer), and various biomarkers implicating its involvement in multiple biological processes and
237 influence in a multitude of health conditions.

238

239 To summarize, of our putatively causal findings, we identified many proteins influencing traits or
240 diseases in the same categories revealing the common mechanistic interplay between specific
241 outcomes. On the contrary, many proteins also demonstrated effects on various traits or diseases
242 that may not be directly linked to each other, underscoring the complexity of protein functions and
243 the intricate network of biological pathways involved in health and disease. For instance, a higher
244 genetically predicted level of MST1 decreased the risk of IBD and its subtypes including both
245 Crohn's disease and ulcerative colitis. This protective effect is likely due to MST1's role in
246 modulating immune responses and inflammation, which are central to the pathogenesis of these

247 conditions. Meanwhile, increased MST1 was associated with adverse cardiovascular outcomes
248 including higher risk of coronary artery disease. In the context of IBD, MST1 may enhance
249 mucosal healing and modulate inflammatory pathways, contributing to its protective effects.
250 Conversely, the impact of MST1 on the cardiovascular system may involve mechanisms related
251 to vascular inflammation and endothelial function, leading to increased blood pressure and
252 atherosclerosis, highlighting the importance of understanding context-specific regulation of these
253 potential targets.

254 **Supplementary Note 5A:** *Validating cardiovascular related putatively causal protein-phenotype*
255 *pairs from prior studies in European ancestries*

256
257 We validated many previously known findings for cardiovascular phenotypes in European
258 ancestries (**Fig. 4a** and **Supplementary Figure 2a**). For instance, COL6A3 (SomaScan aptamer:
259 11196-31, Olink assay: OID20292) was positively associated with coronary artery disease (CAD)
260 in all four European ancestry cohorts. This effect is concordant with our previous extensive work
261 on COL6A3⁵. In addition, we replicated previously reported findings of MMP12 on stroke by Sun
262 et al.⁶ that was also further validated by Zheng et al.⁷ who extended to stroke subtypes. Similar
263 to Zheng's study, European ancestry MMP12 pQTLs from deCODE and UKB-PPP were
264 associated with lower risk of any ischemic stroke (deCODE: OR = 0.92, 95% CI: 0.89–0.95, $P =$
265 1.9×10^{-7} , $PP_{\max} = 0.98$; UKB-PPP: OR = 0.92, 95% CI: 0.90–0.95, $P = 1.9 \times 10^{-7}$, $PP_{\max} = 1$) and
266 large artery stroke (deCODE: OR = 0.77, 95% CI: 0.70–0.86, $P = 6.0 \times 10^{-7}$, $PP_{\max} = 1$; UKB-PPP:
267 OR = 0.79, 95% CI: 0.72–0.87, $P = 6.0 \times 10^{-7}$, $PP_{\max} = 0.99$).

268
269 Additionally, ITIH4 was shown in a prior study using mouse lines and colocalization to act as a
270 novel vascular smooth muscle cell-expressed gene implicated in atherosclerotic plaques⁸.
271 However, genetic evidence of causality was not determined. Here, we found a positive association
272 between ITIH4 with CAD (deCODE: OR = 1.43, 95% CI: 1.27–1.60, $P = 1.5 \times 10^{-9}$, $PP_{\max} = 1$;
273 Fenland: OR = 1.18, 95% CI: 1.12–1.25, $P = 1.5 \times 10^{-9}$, $PP_{\max} = 1$), pulse pressure (deCODE: $\beta =$
274 1.46 , 95% CI: 1.00–1.93, $P = 5.5 \times 10^{-10}$, $PP_{\max} = 1$; Fenland: $\beta = 0.69$, 95% CI: 0.47–0.91, $P =$
275 5.5×10^{-10} , $PP_{\max} = 0.99$), and systolic blood pressure (deCODE: $\beta = 1.66$, 95% CI: 0.98–2.34,
276 $P = 1.8 \times 10^{-6}$, $PP_{\max} = 0.97$; Fenland: $\beta = 0.78$, 95% CI: 0.46–1.11, $P = 1.8 \times 10^{-6}$, $PP_{\max} = 0.94$),
277 consistent with and confirming the findings of earlier research using animal studies.

278
279 Interestingly, we also identified a few proteins that were protective against cardiovascular events.
280 For example, SWAP70 was protective against coronary artery disease (ARIC: OR = 0.95, 95%
281 CI: 0.93–0.96, $P = 5.7 \times 10^{-11}$, $PP_{\max} = 1$; deCODE: OR = 0.92, 95% CI: 0.89–0.96, $P = 1.5 \times 10^{-9}$,
282 $PP_{\max} = 0.94$), small vessel stroke (deCODE: OR = 0.78, 95% CI: 0.68–0.89, $P = 2.6 \times 10^{-4}$,
283 $PP_{\max} = 0.84$), and any ischemic stroke (ARIC: OR = 0.94, 95% CI: 0.92–0.97, $P = 4.5 \times 10^{-6}$,
284 $PP_{\max} = 0.98$; deCODE: OR = 0.90, 95% CI: 0.86–0.95, $P = 3.0 \times 10^{-5}$, $PP_{\max} = 0.92$).

285
286 PTN was protective against peripheral artery disease in two cohorts (Fenland: OR = 0.79, 95%
287 CI: 0.70–0.89, $P = 7.5 \times 10^{-5}$, $PP_{\max} = 0.97$, and UKB-PPP: OR = 0.49, 95% CI: 0.37–0.65, $P =$
288 8.5×10^{-7} , $PP_{\max} = 0.89$), mood swings (deCODE: OR = 0.98, 95% CI: 0.97–0.99, $P = 1.4 \times 10^{-5}$,
289 $PP_{\max} = 0.81$; Fenland: OR = 0.97, 95% CI: 0.96–0.99, $P = 1.4 \times 10^{-5}$, $PP_{\max} = 0.84$), and
290 anthropometric outcomes such as waist-to-hip ratio (deCODE: $\beta = -0.04$, 95% CI: -0.06, -0.03, $P =$
291 2.3×10^{-6} , $PP_{\max} = 0.97$; Fenland: $\beta = -0.04$, 95% CI: -0.07, -0.03, $P = 4.0 \times 10^{-6}$, $PP_{\max} = 0.95$).

292
293 Further, DKKL1 was previously reported as putatively causal for multiple sclerosis⁹ which we also
294 found (ARIC: OR = 0.46, 95% CI: 0.37–0.58, $P = 3.5 \times 10^{-11}$, $PP_{\max} = 1$; Fenland: OR = 0.28, 95%
295 CI: 0.19–0.41, $P = 4.3 \times 10^{-11}$, $PP_{\max} = 1$), but here we also identified it as protective against risk
296 of large artery stroke (ARIC: OR = 0.59, 95% CI: 0.44–0.79, $P = 4.2 \times 10^{-4}$, $PP_{\max} = 0.87$; Fenland:
297 OR = 0.42, 95% CI: 0.26–0.67, $P = 3.0 \times 10^{-4}$, $PP_{\max} = 0.89$) as well as metabolic/endocrine
298 disorders such as hypothyroidism/myxoedema (ARIC: OR = 0.99, 95% CI: 0.98–0.99, $P = 1.2 \times$
299 10^{-5} , $PP_{\max} = 0.95$; Fenland: OR = 0.98, 95% CI: 0.97–0.99, $P = 2.6 \times 10^{-5}$, $PP_{\max} = 0.84$).

300
301
302 **Supplementary Note 5B:** *Validating non-cardiovascular disease related putatively causal*
303 *protein-phenotype pairs from prior studies in European ancestries*

304
305 We also validated findings in other non-cardiovascular disease categories in European ancestries.
306 Network plots for these associations are shown for autoimmune (**Supplementary Figure 2b**),
307 neurological (**Supplementary Figure 2c**), psychiatric (**Supplementary Figure 2d**),
308 metabolic/endocrine (**Supplementary Figure 2e**), and gastrointestinal phenotypes
309 (**Supplementary Figure 2f**).

310
311 For example, a one standard deviation increase in genetically predicted NPNT levels was
312 associated with a decreased risk of asthma which is consistent with findings in our previous work¹⁰.

313
314 Notably, increased levels of genetically predicted RAB21 was protective against Parkinson's
315 disease and associated with increased cognitive performance and educational attainment
316 consistent with findings of the involvement of RAB21 in neuronal development¹¹ (**Supplementary**
317 **Figure 2c**). Further, RAB21 has been implicated in obesity in concord with our findings showing
318 protective effects of RAB21 on visceral (VAT), abdominal subcutaneous (ASAT), and
319 gluteofemoral (GFAT) adipose tissue volumes (**Supplementary Figure 2e**).

320
321 INHBB has previously been implicated in serum urate levels¹² and in our analysis was found to
322 be positively associated with urate and negatively associated with estimated glomerular filtration
323 rate in all four European ancestry cohorts. In addition, we found a positive effect of genetically
324 predicted INHBB levels on risk of type 2 diabetes in the UKB-PPP cohort (OR: 1.09, 95% CI:
325 1.04–1.13 per standard deviation (s.d.) increase in the protein level, $P = 9.8 \times 10^{-5}$, $PP_{\max} = 1$)
326 which had not previously been reported.

327
328 Lastly, STAT3 was positively associated with inflammatory bowel disease but negatively
329 associated with multiple sclerosis which is concordant with recent findings showing opposite
330 effects across these two diseases¹³ and supported by an earlier randomized, placebo-controlled
331 multicenter study showing divergent outcomes of anti-TNF therapies, which are effective for
332 inflammatory bowel disease but worsen multiple sclerosis¹⁴.

333
334
335 **Supplementary Note 5C: Exploratory analyses using ARIC African proteomics cohort to**
336 **assess causal effects on binary cardiovascular and autoimmune-related outcomes in the Million**
337 **Veteran Program**

338
339 We identified 7 putatively causal associations for binary cardiovascular outcomes which are
340 shown in **Supplementary Note Table 8**. The protein PCYOX1 was implicated in all diseases.

341
342
343 **Supplementary Note 5D: Additional note on uniquely instrumentable proteins in East Asian**
344 **ancestry and putatively causal protein-phenotype pairs from these proteins**

345
346 Of the 325 unique protein-phenotype pairs identified in the Kyoto University Nagahama East
347 Asian ancestry cohort, we found that 67 (20.6%) protein-phenotype associations were from 8
348 proteins (ALDH2, ANXA7, APOA1, DDOST, GSS, PLA2G7, PRSS2, UGT1A1) specific to East
349 Asian and not instrumentable by European nor African ancestries. For instance, in European
350 ancestry, ALDH2 had no genome-wide significant pQTLs in ARIC, and upon LD clumping, only
351 had *trans*-pQTLs in UKB-PPP, while in both Fenland and deCODE, the strict *cis*-pQTL did not

352 have the highest V2G score and was filtered out given the risk of horizontal pleiotropy. Similarly,
353 in African ancestries, ALDH2 had no genome-wide significant pQTLs upon LD clumping.

354

355 An example of one association from uniquely instrumentable proteins in East Asian ancestry is
356 APOA1 and cholesterol levels. APOA1 was positively associated with both HDL cholesterol and
357 total cholesterol levels concordant with its function as the main protein in high density
358 lipoproteins mediating efflux of cholesterol. Additionally, causal effects of UGT1A1 on total
359 bilirubin has been previously identified in African ancestries¹⁵ and our study supports these
360 findings in East Asian ancestries ($\beta = -0.44$, 95% CI: -0.46, -0.43, $P = 1.00 \times 10^{-300}$, $PP_{\max} = 1$).

361

362 **Supplementary Note 6: Discordant effects across ancestries for putatively causal protein-**
363 **phenotypes pairs**

364

365 For putatively causal associations with inconsistent MR effect estimates across ancestries, we
366 identified 12 protein-phenotype pairs involving 9 proteins and 6 phenotypes, composed of lipid
367 and anthropometric traits (**Supplementary Figure 3**). One pair showed discordant MR estimates
368 across all three ancestries, four were discordant between European and African ancestries, and
369 seven between European and East Asian ancestries. For instance, ABO was negatively
370 associated with total cholesterol levels in Europeans but positively associated in African and East
371 Asian ancestries. This discrepancy may require further study due to the high-impact PAV
372 instrumental variable used for ABO in African ancestries (**Supplementary Table 15**). Similar
373 discordance was seen with ABO and LDL cholesterol: negative in Europeans and positive in East
374 Asian ancestries, likely due to ABO's pleiotropic nature. CD36 also showed discordant
375 associations: positively associated with HDL cholesterol in Europeans (deCODE, Fenland, UKB-
376 PPP) but negatively in Africans (ARIC, UKB-PPP), and negatively associated with triglycerides in
377 Europeans but positively in Africans. The *cis*-pQTL proxying CD36 in African ancestries was a
378 high-impact PAV. While increased CD36 typically decreases HDL and increases triglycerides, a
379 previous study showed an inverse relationship between monocyte CD36 and HDL in African
380 ancestries¹⁶, aligning with our findings. Other discordant associations included DEF6 with height
381 (negative in Europeans, positive in Africans) and CA4 (positive in Europeans, negative in
382 Africans). Between European and East Asian ancestries, discordance was found for GHR and
383 AOC1 with height, APOB with LDL and total cholesterol, and ACP1 with body mass index. Notably,
384 GHR and height associations were inconsistent within European cohorts (deCODE and UKB-
385 PPP), likely due to differences in proteomics platforms.

386

387 We also identified discordant effects for phenotypically related outcomes that were not exact
388 matches and highlight an example using APOB. APOB plays a predominant role in the etiology
389 of coronary artery disease as shown in recent studies¹⁷⁻¹⁹. Likewise, our results showed that
390 APOB was positively associated with coronary artery disease (CAD) in European ancestries with
391 evidence in deCODE ($\beta = 0.65$, 95% CI: 0.51–0.80, $P = 3.4 \times 10^{-18}$, $PP_{\max} = 1$), and Fenland ($\beta =$
392 0.43 , 95% CI: 0.33–0.53, $P = 2.9 \times 10^{-18}$, $PP_{\max} = 1$). However, APOB in East Asian ancestries
393 was found to be negatively associated with myocardial infarction ($\beta = -0.08$, 95% CI: -0.11,-0.05,
394 $P = 1.4 \times 10^{-8}$, $PP_{\max} = 1$), LDL cholesterol ($\beta = -0.06$, 95% CI: -0.07, -0.05, $P = 1.3 \times 10^{-30}$, PP_{\max}
395 $= 1$), HMG CoA reductase inhibitors ($\beta = -0.14$, 95% CI: -0.16, -0.12, $P = 3.1 \times 10^{-44}$, $PP_{\max} = 1$),
396 and vasodilators used in cardiac diseases ($\beta = -0.06$, 95% CI: -0.08, -0.03, $P = 5.0 \times 10^{-6}$, PP_{\max}
397 $= 0.98$). When querying the instruments used for APOB in European ancestries in Open Targets
398 Genetics we found that the single *cis*-pQTL proxying APOB in deCODE, rs563290, and Fenland,
399 rs541041, were intergenic variants (Ensembl VEP impact: Modifier). In contrast, the most severe
400 consequence of the pQTL for APOB in East Asian ancestries, rs13306194, was missense
401 (Ensembl VEP impact: Moderate) and could potentially be altering epitope binding rather than
402 being a true biological signal. Nonetheless, this pQTL may still hold biological significance due to
403 being the top hit from variant-to-gene mapping, although further investigation may be required.

404

405 In summary, while inconsistent effects were found across ancestries for a few protein-phenotype
406 associations we highlight that in three associations, ABO with total cholesterol levels, CD36 with
407 HDL cholesterol levels, and CD36 with triglycerides, the protein level in African ancestries was a
408 PAV of high impact so we advise caution in the interpretation of these results. Further, ABO is
409 known to play a multi-faceted role in diseases and pQTLs at this locus have been associated with
410 many proteins⁶. However, since we used variant-to-gene mapping which leverages biological
411 evidence to select instruments, these PAVs of high impact may potentially still be functionally

412 relevant. Notably, we found that decreased CD36 in African ancestries was associated with
413 increased HDL cholesterol which was consistent with findings from a previous study¹⁶. Thus,
414 further exploration may be required with larger sample sizes to elucidate whether these findings
415 are biologically plausible.
416

417 **Supplementary Note 7A: Druggability of instrumentable protein-coding genes at the cohort**
418 *level*

419
420 We compared instrumentable protein-coding genes against the druggable genome composed of
421 4,479 genes from Finan et al.²⁰ which classifies genes into Tier 1, 2, or 3 according to druggability.
422 Tier 1 refers to efficacy targets of approved small molecules, biotherapeutic drugs, and clinical-
423 phase drug candidates; Tier 2 includes proteins closely associated with drug targets or linked to
424 drug-like compounds; Tier 3 encompasses secreted or extracellular proteins, those distantly
425 related to approved drug targets, and proteins from important druggable gene families not covered
426 in Tier 1 or Tier 2. All ancestries had proportionally comparable number of instrumentable protein-
427 coding genes in Tier 1 and 2 (**Supplementary Figure 4**).

428
429 We found that 71, 29, and 210 proteins were shared in Tier 1, Tier 2, and Tier 3 across three
430 ancestries, respectively (**Supplementary Figure 5**) while 26, 10, and 78 proteins were shared in
431 Tier 1, Tier 2, and Tier 3 among all seven cohorts across three ancestries, respectively
432 (**Supplementary Figure 6**).

433
434
435 **Supplementary Note 7B: Overlap of protein-phenotype pairs stratified by ancestry in the**
436 *druggable genome and DrugBank*

437
438 *7B.1 Druggable genome*

439 We found that 57.7%, 78.5% and 74.2% of putatively causal protein-phenotype associations in
440 European, African, and East Asian ancestries, respectively, overlapped with the druggable
441 genome (**Supplementary Note Table 9**).

442
443 *7B.2. DrugBank*

444 Across ancestries, a similar proportion of proteins from the putatively causal protein-phenotype
445 associations—33.6% in European, 35.7% in African and 35.5% in East Asian ancestry—had
446 approved or investigational drugs available based on DrugBank²¹ (**Supplementary Note Tables**
447 **10–12**).

448
449
450 **Supplementary Note 7C: Druggability of protein-phenotype pairs by integrating the druggable**
451 *genome, DrugBank, and Open Targets Platform*

452
453 We provide druggability visualization for proteins implicated in various diseases (stratified by
454 disease category) which may be potentially explored as opportunities for drug development for
455 European (**Supplementary Figure 7**) and East Asian ancestries (**Supplementary Figure 8**). For
456 instance, increased genetically predicted ANGPTL4 (Tier 3 target) leads to increased risk of CAD
457 (**Supplementary Figure 7 - Cardiovascular**).

458

459 **Supplementary Note 8: Prioritization of targets for CAD and T2D**

460

461 We applied filtering steps to prioritize proteins involved in CAD (**Supplementary Figure 9a**) and
462 T2D (**Supplementary Figure 9b**). See **Supplementary Note 8 Methods** below. In European
463 ancestries, we found directional concordance between MR estimates and hazard ratios from
464 Cox regression for incident CAD for 18 proteins, ANGPTL4, C1R, C1S, COL6A3, COMT, DDT,
465 DUSP13, FES, FN1, IL6R, ITIH4, MST1, PCSK9, PDE5A, PLG, SCARF2, TGFB1, and TIMP2.
466 Two of these proteins, ITIH4 and ANGPTL4 were putatively causal for more than one
467 phenotype in African ancestries, albeit for different outcomes, while three proteins, IL6R,
468 PCSK9, and PLG were putatively causal for more than one phenotype in East Asian ancestries
469 (**Supplementary Figure 9a, Supplementary Note Table 13**).

470

471 We also found directional concordance between MR estimates and hazard ratios from Cox
472 regression for incident T2D for 8 proteins, ACE, ANGPTL4, INHBB, LRIG1, MINDY1, PAM,
473 PAPP, and TFRC in European ancestries. ANGPTL4 was the only putatively causal protein from
474 this list present in African ancestries while in East Asian ancestries, three of these proteins, INHBB,
475 LRIG1, and TFRC were putatively causal (**Supplementary Figure 9b, Supplementary Note
476 Table 14**).

477

478 We found that, in European ancestries, each standard deviation increase in ANGPTL4 levels was
479 associated with increased odds of incident CAD (OR = 1.17, SE = 0.016, $P = 1.89 \times 10^{-22}$) and
480 increased odds of incident T2D (OR = 1.21, SE = 0.023, $P = 4.02 \times 10^{-17}$). These results are
481 consistent with our findings from MR, where increased circulating ANGPTL4 levels were
482 associated with increased risk of CAD and T2D. Notably, MR estimates in African ancestries for
483 ANGPTL4 also supported this concordance in European ancestries with ANGPTL4 being
484 negatively associated with high density lipoprotein cholesterol levels and positively associated
485 with triglycerides supporting ANGPTL4 as a potential therapeutic target for intervention.

486

487 In addition, each standard deviation increase in INHBB levels was associated with a 1.19-fold
488 increased hazard of T2D (SE = 0.022, $P = 3.63 \times 10^{-14}$), aligning with MR findings of increased
489 T2D risk. MR evidence in East Asian ancestries showed that higher genetically predicted INHBB
490 levels increase the risk of blood urea nitrogen and G-glutamyl transpeptidase, both linked to T2D
491 risk. However, in East Asian ancestries, reducing INHBB levels might lower HDL cholesterol and
492 raise LDL cholesterol, potentially increasing cardiovascular risk. Thus, therapeutic strategies
493 targeting INHBB must be carefully evaluated for adverse lipid profile effects. Comprehensive
494 research is needed to ensure benefits outweigh risks and to develop strategies that selectively
495 modulate INHBB without harming cardiovascular health.

496

497 We found corroborative evidence of causality between ANGPTL4 and coronary artery disease
498 and type 2 diabetes which was validated through observational association analyses on incident
499 coronary artery disease and incident type 2 diabetes risk in European ancestries. Additionally,
500 through MR we also identified similar causal roles for ANGPTL4 in African ancestries for related
501 biomarkers such as HDL cholesterol and triglycerides which were in directions congruent with our
502 CAD and T2D findings. ANGPTL4 is an inhibitor of lipoprotein lipase (LPL) which leads to
503 increased triglyceride levels and prior studies have shown that the ANGPTL4 coding variant E40K
504 has been associated with lower plasma triglyceride levels²² and lower risk of both CAD and T2D²³.
505 While no current therapies exist for ANGPTL4, a closely related protein ANGPTL3, which also
506 inhibits LPL does and is targeted by zolasiran, an RNA interference therapy. Zolasiran targets
507 ANGPTL3 expression in the liver and demonstrated efficacy in reducing triglyceride levels in
508 patients with mixed hyperlipidemia²⁴. Mechanistically, ANGPTL4 and ANGPTL3 act differently.
509 Whereas ANGPTL3 inhibitory activity on LPL is hindered through binding to heparin, ANGPTL4

510 is unaffected by heparin binding suggesting that ANGPTL4 may employ distinct regulatory
511 mechanisms in modulating LPL activity, potentially involving alternative molecular interactions or
512 structural characteristics that confer resistance to heparin inhibition. Further research into these
513 mechanisms could unveil novel therapeutic strategies for managing cardiovascular diseases.

514
515

516 **Supplementary Note 8 Methods**

517

518 *8.1. Prioritizing targets for CAD and T2D*

519 For European protein-phenotype associations, we first subsetted to those with consistent MR
520 effect across all four cohorts (ARIC, deCODE, Fenland, and UKB-PPPP) then integrated Cox
521 regression effects and determined directional concordance between MR effect estimates and
522 observational association estimates. Those with discordance between the two estimates were
523 removed and the remaining proteins were retained as potential candidates. We performed this
524 procedure for both incident CAD and incident T2D. A detailed flow diagram is shown in

525 **Supplementary Figure 9.**

526

527 We highlight that when comparing the direction of MR effect estimates with observational
528 association estimates, we removed proteins with inconsistent direction and those which did not
529 have an observational association estimate. Since Cox regression was performed on the UKB-
530 PPP Olink Explore 3072 proteins, MR effect estimates from SomaScan v4 proteins would not
531 have a corresponding observational association estimate meaning proteins exclusive to
532 SomaScan v4 were not considered. Therefore, only proteins from Olink or common proteins
533 between SomaScan and Olink were analyzed in this analysis.

534

535 *8.2. Observational associations between circulating protein abundances and incident CAD and* 536 *T2D in the UK Biobank*

537 We assessed whether MR effect estimates were in alignment with observational associations as
538 this can provide an additional source of evidence supporting the purported protein-phenotype
539 association. To perform observational association analysis on incident CAD and T2D, we used
540 individual level data from the UK Biobank to determine whether circulating protein abundances
541 were able to predict future risk of these diseases based on 10 years of follow-up.

542

543 CAD was defined as in our previous study⁵. Briefly, we used three criteria: (i) a record of ICD-10
544 codes I20-I25 (ischemic heart disease), (ii) an operation record of percutaneous transluminal
545 coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG), and (iii) a death record
546 associated with ICD-10 codes I20-I25. The time to event was determined by subtracting the event
547 registration date from the enrollment date (data field: 53), focusing on events occurring within 10
548 years of enrollment. We excluded individuals with pre-existing CAD who met these criteria prior
549 to enrollment, as well as those without a recorded event date. Controls were defined as individuals
550 without a CAD record based on doctor diagnosis (data field: 6150), self-reported heart attack
551 (data field: 20002), or an ICD-10 record of I20-I25.

552

553 T2D was defined using ICD-10 code E-11 while controls were defined as individuals without any
554 type of diabetes based on self-reports.

555

556 We used Cox proportional hazards models (function: `coxph()`) adjusting for age, sex, BMI,
557 recruitment center, time to Olink processing, batch, and the first 10 principal components to
558 associate 2,922 Olink 3072 Explore platform proteins from 4,750 cases with incident CAD and
559 32,565 controls and 3,066 cases with incident T2D and 37,453 controls. Protein levels were
560 inverse rank normal transformed prior to analysis.

561 **Supplementary Note 9: Detailed description of Kyoto University Nagahama East Asian cohort**

562

563 **9.1. Study Cohort**

564 Whole-genome sequencing (WGS) and proteome analysis were conducted using samples from
565 the Nagahama Prospective Genome Cohort for Comprehensive Human Bioscience (Nagahama
566 Study). A subset of 2,000 individuals (1,392 women, mean age 56.7 years; 608 men, mean age
567 62.0 years) was selected from 8,559 participants in the first follow-up health check (2012-2016).
568 Ethical approval was obtained from the Kyoto University Graduate School of Medicine and the
569 Nagahama Municipal Review Board (No. 278). All participants provided written informed
570 consent.

571

572 **9.2. Plasma Samples and Protein Quantification**

573 Plasma was isolated from EDTA-treated blood by centrifugation and stored at -80°C . Protein
574 levels were measured using SomaScan assay v4, targeting 4,740 unique proteins with 5,284
575 SOMAmers. After quality control, 1,997 plasma samples and 4,392 SOMAmers (4,196 proteins)
576 were retained. Data were normalized and used for protein quantitative trait locus (pQTL)
577 analysis. Some proteins had multiple SOMAmers targeting different forms, distinguished by
578 annotations in the Somald and Target columns.

579

580 **9.3. Whole-Genome Sequencing**

581 WGS was performed on 1,573 samples using Illumina platforms and 385 samples using a
582 DNBSEQ-G400 instrument, following standard protocols (GATK and DRAGEN). After quality
583 control, including kinship analysis and variant concordance checks, 1,823 samples and
584 4,642,253 variants were retained for protein association analysis.

585

586 **9.4. pQTL Analysis**

587 Genetic associations with 4,392 SOMAmers were analyzed using PLINK (v.2.00a3LM) with age,
588 sex, variant-calling pipeline, and the first five genetic principal components as covariates. The
589 genome-wide significance threshold was set at 1.08×10^{-8} after Bonferroni correction.

590

591 **9.5. Linkage Disequilibrium (LD) Clumping**

592 LD clumping was performed using PLINK, defining clumping regions as 500 kb around index
593 variants with an LD threshold of $R^2 \geq 0.8$. Each region was assigned a unique ID.

594

595 **9.6. Conditional Analysis**

596 Independent signals at the loci were identified through stepwise selection in GCTA-COJO with
597 the following parameters: --maf 0.01 --cojo-slct, --cojo-collinear 0.9 --cojo-p 5e-8

598

599

600

601 **Supplementary Note 10: Detailed description of PWCoCo and SharePro**

602

603 We performed colocalization analyses using PWCoCo and SharePro as complementary methods
604 to safeguard against potential putative causal associations confounded by LD and ensure higher
605 confidence in our findings. Since differences in LD structures between populations under study
606 can introduce bias in MR analyses, the presence of a shared causal variant between the exposure
607 and outcome can help mitigate this issue and increase the robustness of the MR findings.

608

609 *10.1. Pairwise conditional and colocalization analysis (PWCoCo)*

610

611 Pairwise conditional and colocalization analysis (PWCoCo) (<https://github.com/jwr-git/pwcoco>)
612 integrates methods from conditional analyses (GCTA-COJO)²⁵ and colocalization analyses
613 (coloc)²⁶ which relaxes the simplified single causal variant assumption of coloc thereby allowing
614 the assessment of whether multiple causal variants exist and colocalize within a region. Through
615 conditional analyses, independent signals from both traits (here protein GWAS and outcome
616 GWAS) can be identified and colocalization can be conducted on each pair of conditionally
617 independent signals for the two GWAS while upholding the strict single variant assumption of
618 coloc. PWCoCo has been shown to outperform existing methods in scenarios where the single
619 variant assumption is violated²⁷. It also enables the identification of previously missed disease-
620 causing variants through its ability to perform independent colocalization of secondary signals
621 and offers key improvements through its computational efficiency and ease-of-use. We performed
622 PWCoCo using default settings and set the maximum number of causal variants in the region, k ,
623 to 5. PWCoCo, similar to coloc, reports five colocalization probabilities: H0 – no association with
624 either trait; H1 – association with trait 1, not with trait 2; H2 – association with trait 2, not with trait
625 1; H3 – association with trait 1 and trait 2, two independent SNPs; H4 – association with trait 1
626 and trait 2, one shared SNP (i.e., the probability that both traits are associated through the sharing
627 of a single causal variant). We considered the maximum H4 posterior probability (PPH4) across
628 all tested pairs of conditionally independent signals and report evidence of colocalization if the
629 maximum PPH4 ≥ 0.8 . We note that this is different from PP_{\max} used in the main text which we
630 use to denote the maximum PP between PWCoCo and SharePro colocalization methods.

631

632 *10.2. Shared sparse Projection for colocalization analysis (SharePro)*

633

634 Shared sparse Projection for colocalization analysis (SharePro)
635 (https://github.com/zhwm/SharePro_coloc) is a novel colocalization method which extends upon
636 the coloc framework. SharePro uses an efficient variational inference algorithm that leverages LD
637 modelling and integration with colocalization assessment through grouping of correlated variants
638 into effect groups to accurately estimate posterior colocalization probabilities which together
639 overcome the aforementioned limitations. Further, SharePro has increased power for identifying
640 biologically plausible signals in simulation analyses, outperforming coloc and PWCoCo while
641 maintaining low computational cost and a low false positive rate²⁸. We used SharePro (v.5.0.0)
642 default settings which sets the maximum number of causal variants in the region, K , to 10.

643

644 We emphasize that for SharePro, when K is larger than the true number of causal variants, it
645 consistently provides adequate results in comparison to setting K to the true number of causal
646 variants. Namely, $K = 10$ should always yield results similar to, or better than $K = 5$ which was set
647 in PWCoCo due to the COJO step requiring a substantial increase in computational time with a
648 larger defined K , which is not the case in SharePro.

649

650 For the required LD input files to SharePro, we used the UKB 50k reference panel for European,
651 the HGDP + 1kGP reference panel for African, and the 1kGP East Asian reference panel for East

652 Asian ancestries similar to what we utilized at the LD clumping stage previously described.
653 SharePro reports the “share” column (colocalization probabilities) for all effect groups, and we
654 reported evidence of colocalization for the protein GWAS and outcome GWAS pair if the
655 maximum colocalization probability of any effect group was > 0.8 . We also note that this is
656 different from PP_{\max} used in the main text which we use to denote the maximum PP between
657 PWCoCo and SharePro colocalization methods.
658

Supplementary Note 11:

STROBE-MR checklist of recommended items to address in reports of Mendelian randomization studies^{1 2}

Note: Page number will be added at the proof-reading stage.

| Item No. | Section | Checklist item | Page No. | Relevant text from manuscript |
|---------------------|--------------------------------------|---|----------|--|
| 1 | TITLE and ABSTRACT | Indicate Mendelian randomization (MR) as the study's design in the title and/or the abstract if that is a main purpose of the study | 1, 2 | Specified in the title abstract |
| INTRODUCTION | | | | |
| 2 | Background | Explain the scientific background and rationale for the reported study. What is the exposure? Is a potential causal relationship between exposure and outcome plausible? Justify why MR is a helpful method to address the study question | 3 | Explained in paragraph 1 of the introduction section. |
| 3 | Objectives | State specific objectives clearly, including pre-specified causal hypotheses (if any). State that MR is a method that, under specific assumptions, intends to estimate causal effects | 3 | Explained in paragraph 1 of the introduction section. |
| METHODS | | | | |
| 4 | Study design and data sources | Present key elements of the study design early in the article. Consider including a table listing sources of data for all phases of the study. For each data source contributing to the analysis, describe the following: | | Explained in the Methods section and sources of data are presented in supplementary table 1 (ST10-12). |
| | | a) Setting: Describe the study design and the underlying population, if possible. Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection, when available. | | The study design and the underlying population are described in the Methods section. The remainder are described in the main text. |
| | | b) Participants: Give the eligibility criteria, and the sources and methods of selection of participants. Report the sample size, and whether any power or sample size calculations were carried out prior to the main analysis | | (b)–(e) were described in the Methods section and Supplementary Note |
| | | c) Describe measurement, quality control and selection of genetic variants | | |
| | | d) For each exposure, outcome, and other relevant variables, describe methods of assessment and diagnostic criteria for diseases | | |
| | | e) Provide details of ethics committee approval and participant informed consent, if relevant | | |
| 5 | Assumptions | Explicitly state the three core IV assumptions for the main analysis (relevance, independence and exclusion restriction) as well assumptions for any additional or sensitivity analysis | | Explicitly stated in the introduction and in the Methods. |

| | | | |
|---|---|---|---|
| 6 | Statistical methods: main analysis | Describe statistical methods and statistics used | |
| | | a) Describe how quantitative variables were handled in the analyses (i.e., scale, units, model) | (a)–(e) were described in the Methods as well as the Results section. |
| | | b) Describe how genetic variants were handled in the analyses and, if applicable, how their weights were selected | |
| | | c) Describe the MR estimator (e.g. two-stage least squares, Wald ratio) and related statistics. Detail the included covariates and, in case of two-sample MR, whether the same covariate set was used for adjustment in the two samples | |
| | | d) Explain how missing data were addressed | |
| | | e) If applicable, indicate how multiple testing was addressed | |
| 7 | Assessment of assumptions | Describe any methods or prior knowledge used to assess the assumptions or justify their validity | 7–9 were described in the Methods section as well as the Results section. |
| 8 | Sensitivity analyses and additional analyses | Describe any sensitivity analyses or additional analyses performed (e.g. comparison of effect estimates from different approaches, independent replication, bias analytic techniques, validation of instruments, simulations) | |
| 9 | Software and pre-registration | | |
| | | a) Name statistical software and package(s), including version and settings used | |
| | | b) State whether the study protocol and details were pre-registered (as well as when and where) | |

RESULTS

| | | | |
|----|-------------------------|--|--|
| 10 | Descriptive data | | |
| | | a) Report the numbers of individuals at each stage of included studies and reasons for exclusion. Consider use of a flow diagram | Described in the Methods and Supplementary Tables. |
| | | b) Report summary statistics for phenotypic exposure(s), outcome(s), and other relevant variables (e.g. means, SDs, proportions) | Described in the Methods and Supplementary Tables. |
| | | c) If the data sources include meta-analyses of previous studies, provide the assessments of heterogeneity across these studies | Discussed in the original papers. We also evaluated the heterogeneity and horizontal pleiotropy in our analyses. |

| | | |
|-----------|--|--|
| | <ul style="list-style-type: none"> d) For two-sample MR: <ul style="list-style-type: none"> i. Provide justification of the similarity of the genetic variant-exposure associations between the exposure and outcome samples ii. Provide information on the number of individuals who overlap between the exposure and outcome studies | Described in the Methods, Results, and Supplementary Note. |
| 11 | Main results | |
| | a) Report the associations between genetic variant and exposure, and between genetic variant and outcome, preferably on an interpretable scale | (a)–(c) were described in the Results. |
| | b) Report MR estimates of the relationship between exposure and outcome, and the measures of uncertainty from the MR analysis, on an interpretable scale, such as odds ratio or relative risk per SD difference | |
| | c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | |
| | d) Consider plots to visualize results (e.g. forest plot, scatterplot of associations between genetic variants and outcome versus between genetic variants and exposure) | Described in the Methods, Results, Main Figures and Supplementary Figures using forest plots. |
| 12 | Assessment of assumptions | |
| | a) Report the assessment of the validity of the assumptions | Described in the Methods and Results. |
| | b) Report any additional statistics (e.g., assessments of heterogeneity across genetic variants, such as I^2 , Q statistic or E-value) | Described in the Methods and Results. |
| 13 | Sensitivity analyses and additional analyses | |
| | a) Report any sensitivity analyses to assess the robustness of the main results to violations of the assumptions | (a)–(d) were described in the Methods and Results. |
| | b) Report results from other sensitivity analyses or additional analyses | |
| | c) Report any assessment of direction of causal relationship (e.g., bidirectional MR) | |
| | d) When relevant, report and compare with estimates from non-MR analyses | |
| | e) Consider additional plots to visualize results (e.g., leave-one-out analyses) | We did not perform leave-one-out analyses but assessed the robustness of the analyses using two colocalization methods (PWCoCo and SharePro) |

| | | | |
|--------------------------|------------------------------|---|--|
| | | | which are described in the Methods, Results, and Supplementary Note. |
| DISCUSSION | | | |
| 14 | Key results | Summarize key results with reference to study objectives | Described in the Discussion. |
| 15 | Limitations | Discuss limitations of the study, taking into account the validity of the IV assumptions, other sources of potential bias, and imprecision. Discuss both direction and magnitude of any potential bias and any efforts to address them | Described in the Discussion. |
| 16 | Interpretation | <p>a) Meaning: Give a cautious overall interpretation of results in the context of their limitations and in comparison with other studies</p> <p>b) Mechanism: Discuss underlying biological mechanisms that could drive a potential causal relationship between the investigated exposure and the outcome, and whether the gene-environment equivalence assumption is reasonable. Use causal language carefully, clarifying that IV estimates may provide causal effects only under certain assumptions</p> <p>c) Clinical relevance: Discuss whether the results have clinical or public policy relevance, and to what extent they inform effect sizes of possible interventions</p> | (a)–(c) were described in the Results and Discussion. |
| 17 | Generalizability | Discuss the generalizability of the study results (a) to other populations, (b) across other exposure periods/timings, and (c) across other levels of exposure | Described in the limitations section in the Discussion. |
| OTHER INFORMATION | | | |
| 18 | Funding | Describe sources of funding and the role of funders in the present study and, if applicable, sources of funding for the databases and original study or studies on which the present study is based | Described in the Acknowledgments. |
| 19 | Data and data sharing | Provide the data used to perform all analyses or report where and how the data can be accessed, and reference these sources in the article. Provide the statistical code needed to reproduce the results in the article, or report whether the code is publicly accessible and if so, where | Described in the Data Availability and Code availability. |
| 20 | Conflicts of Interest | All authors should declare all potential conflicts of interest | Described in the Competing Interests |

This checklist is copyrighted by the Equator Network under the Creative Commons Attribution 3.0 Unported (CC BY 3.0) license.


1. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomization (STROBE-MR) Statement. JAMA. 2021;under review.

2. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomisation (STROBE-MR): Explanation and Elaboration. *BMJ*. 2021;375:n2233.


Supplementary Figure 1. Within-ancestry *cis*-pQTL effect size concordance.

Cis-pQTL effect size concordance for (a) European and (b) African ancestry cohorts. In European and African ancestry proteomics cohorts, the effect allele of *cis*-pQTLs in each cohort was aligned to the minor allele of the corresponding variant in their respective reference panels—UKB 50k for European and HGDP+1kGP for African ancestry—to harmonize alleles across each ancestral cohort for plotting. Red line is the diagonal while blue line is the best-fit line with standard errors shown by blue shading. Horizontal and vertical gray dashed lines show $y = 0$ and $x = 0$, respectively.

(a) European ancestry cohorts pairwise comparison



(b) African ancestry cohorts pairwise comparison



Supplementary Figure 2. Protein-phenotype network plots for other phenotypes in European ancestry; six phenotype categories)



Significant estimates between proteins (orange circles) and traits (green rectangles). Arrow thickness indicates how often a protein measurement has a causal effect on the outcome trait. For simplicity, we only depict protein-phenotype pairs in which all European cohorts showed concordant direction of effect estimates. Red arrows indicate a positive causal estimate of the protein on the outcome while blue arrows indicate a negative causal estimate of the protein on the outcome.

- a. Cardiovascular (binary traits only)
- b. Autoimmune
- c. Neurological
- d. Psychiatric
- e. Metabolic/endocrine
- f. Gastrointestinal


We note the following:

- Eczema appears in both Autoimmune and Skin network plots
- Type 1 diabetes appears in both Autoimmune and Metabolic/endocrine network plots
- Inflammatory bowel disease, Ulcerative colitis, Crohn's disease, and Celiac disease appear in both Autoimmune and Gastrointestinal network plots


a. Cardiovascular (binary traits only)



c. Neurological




e. Metabolic/endocrine




- Complex trait (outcome)
- Protein trait (exposure)
- Positive causal estimate
- Negative causal estimate
- ← Seven significant estimates
- ← Six significant estimates
- ← Five significant estimates
- ← Four significant estimates
- ← Three significant estimates
- ← Two significant estimates
- ← One significant estimate

f. Gastrointestinal




Supplementary Figure 3. Protein-phenotype pairs with discordant across ancestries. Protein-phenotype associations that have an estimated causal effect (FDR < 0.05), passed MR sensitivity analyses, and colocalized (PP.H4 > 0.8) in either PWCoCo or SharePro but had inconsistent direction of MR effect estimates across ancestries. Sample sizes for each outcome can be found in Supplementary Tables 13, 14, and 15 for European, African, and East Asian ancestries, respectively.



Supplementary Figure 4. The overlap between instrumentable protein-coding genes and the druggable genome from Finan et al.


The number of proteins classified into each tier when normalized by the number of instrumentable protein coding genes.




Supplementary Figure 5. UpSet plot showing the overlap between instrumentable proteins and the druggable genome across three ancestries.

(a) Tier 1, (b) Tier 2, (c) Tier 3, and (d) Unclassified groupings from Finan et al. The height of bars in the graphs display the number of instrumentable proteins common to a given cohort configuration. The x-axis shows the different cohort configurations. Horizontal bar graphs along with dots indicate a specific ancestry cohort and their frequency with ancestry denoted by shading (Green shading: East Asian ancestry cohort; Blue shading: African ancestry cohorts; Light red shading: European ancestry cohorts). The vertical red bar and red dotted line denote instrumentable proteins common to all cohorts across all three ancestries.


Tier 1




Tier 2



Tier 3



Unclassified



Supplementary Figure 7. European ancestry druggability heatmaps for 12 disease categories.

In the following supplementary figures, we show druggability heatmaps for different disease categories in European ancestries.

Cell color displays the MR effect estimate based on Z score averaged across cohorts capped at -10 to +10 with red showing a positive Z score indicating a positive MR effect of the protein on the phenotype and blue showing a negative Z score indicating a negative MR effect of the protein on the phenotype. For simplicity, in European ancestries, we only display protein-phenotypes with consistent effect across European cohorts. The y-axis shows the three drug databases. DrugBank (yellow square): DrugBank shows whether the protein has an available drug in the database. OpenTargets (pink square): Open Targets Platform shows whether the protein has available clinical trial information. Druggability: The druggable genome (as defined by Finan et al.) is shown for Tiers 1 (dark green, representing efficacy targets of approved small molecules and biotherapeutic drugs), Tier 2 (dark purple, representing proteins closely related to approved drug targets or which have associated drug-like compounds), Tier 3 (light purple, representing secreted or extracellular proteins, those distantly related to approved drug targets, and members of important druggable gene families not covered in Tier 1 or Tier 2), and Unclassified (gray, all other proteins not in Tiers 1 to 3). Proteins on the y-axis within each are sorted based on the number of supported databases.

In total, for Europeans, we assessed 15 different disease categories.

However, here, we only show heatmaps for 12 disease categories and we do not show the following 3 disease categories:

- Anthropometry, due to the sheer size
- Biomarker, due to the sheer size and
- Reproductive and urogenital system, since there was only a single association.

The remaining 12 disease categories are as follows:

1. Cardiovascular

- since Figure 7 already shows Tier 1 and Tier 2 for Cardiovascular diseases, we show Cardiovascular Tier 3 and Cardiovascular Unclassified here.


2. Autoimmune

- We show the entire Autoimmune heatmap here (including Tier 3 and Unclassified) while Figure 7 only shows Tier 1 and Tier 2 for Autoimmune diseases.


For the remaining diseases, we do not stratify by druggability tier and show all protein-phenotypes together in the heatmaps.

3. Renal
4. Respiratory
5. Metabolic/endocrine
6. Neurological
7. Psychiatric
8. Musculoskeletal
9. Gastrointestinal
10. Miscellaneous
11. Eye
12. Cancer (all cancers are grouped together for simplicity which encompasses the following) Cancer/Skin
Cancer/Metabolic disease
Cancer Cancer/Respiratory
Cancer/Neurological and psychiatric
Cancer/Gastrointestinal
Cancer/Renal


2. Autoimmune




3. Renal




4. Respiratory




9. Gastrointestinal




10. Miscellaneous



11. Eye



12. Cancer



Supplementary Figure 8. East Asian ancestry druggability heatmaps for 11 disease categories.

In the following supplementary figures, we show druggability heatmaps for East Asian disease categories. Cell color displays the MR effect estimate based on Z score averaged across cohorts capped at -10 to +10 with red showing a positive Z score indicating a positive MR effect of the protein on the phenotype and blue showing a negative Z score indicating a negative MR effect of the protein on the phenotype. For simplicity, in European ancestries, we only display protein-phenotypes with consistent effect across European cohorts. The y-axis shows the three drug databases. DrugBank (yellow square): DrugBank shows whether the protein has an available drug in the database. OpenTargets (pink square): Open Targets Platform shows whether the protein has available clinical trial information. Druggability: The druggable genome (as defined by Finan et al.) is shown for Tiers 1 (dark green, representing efficacy targets of approved small molecules and biotherapeutic drugs), Tier 2 (dark purple, representing proteins closely related to approved drug targets or which have associated drug-like compounds), Tier 3 (light purple, representing secreted or extracellular proteins, those distantly related to approved drug targets, and members of important druggable gene families not covered in Tier 1 or Tier 2), and Unclassified (gray, all other proteins not in Tiers 1 to 3). Proteins on the y-axis within each are sorted based on the number of supported databases.


In total, for East Asians, we assessed 14 different disease categories. However, here, we only show heatmaps for 11 disease categories and we do not show the following 3 disease categories:

- Renal, since there was only a single association.
- Eye, since there was only a single association.
- Autoimmune, since the heatmap for all proteins is already shown in Figure 8.


For the remaining diseases, we do not stratify by druggability tier and show all protein-phenotypes together in the heatmaps. All diseases are shown separately except for Neurological and Psychiatric which we group together in one heatmap for simplicity. The remaining 11 disease categories are as follows:

1. Cardiovascular
 - We show the entire Cardiovascular heatmap here (including Tier 3 and Unclassified) while Figure 8 only shows Tier 1 and Tier 2 for Cardiovascular diseases.
- 2. Respiratory
- 3. Metabolic/endocrine
- 4. Neurological+Psychiatric (shown together for simplicity)
- 5. Gastrointestinal
- 6. Miscellaneous
- 7. Cancer
- 8. Haematology
- 9. Anthropometry
- 10. Biomarker


7. Cancer




9. Anthropometry



8. Haematology






10. Biomarker



Supplementary Figure 9. Prioritizing proteins for coronary artery disease and type 2 diabetes.

Flow diagram showing filtering steps for MR estimates and Cox regression observational estimates to identify potential targets for (a) coronary artery disease and (b) type 2 diabetes. CAD = coronary artery disease; OR = odds ratio; T2D: Type 2 diabetes.



664 **Supplementary Note-only References**

- 665 1. Burgess, S., Davies, N. M. & Thompson, S. G. Bias due to participant overlap in two-sample
666 Mendelian randomization. *Genetic Epidemiology* **40**, 597–608 (2016).
- 667 2. Yuan, S. *et al.* Plasma proteins and onset of type 2 diabetes and diabetic complications:
668 Proteome-wide Mendelian randomization and colocalization analyses. *Cell Reports Medicine*
669 **4**, 101174 (2023).
- 670 3. High-Throughput Characterization of Blood Serum Proteomics of IBD Patients with Respect
671 to Aging and Genetic Factors | PLOS Genetics.
672 <https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006565>.
- 673 4. Identification of Common and Rare Genetic Variation Associated With Plasma Protein Levels
674 Using Whole-Exome Sequencing and Mass Spectrometry | Circulation: Genomic and
675 Precision Medicine. <https://www.ahajournals.org/doi/10.1161/CIRCGEN.118.002170>.
- 676 5. Yoshiji, S. *et al.* COL6A3-derived endotrophin mediates the effect of obesity on coronary
677 artery disease: an integrative proteogenomics analysis. 2023.04.19.23288706 Preprint at
678 <https://doi.org/10.1101/2023.04.19.23288706> (2023).
- 679 6. Sun, B. B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73–79 (2018).
- 680 7. Zheng, J. *et al.* Phenome-wide Mendelian randomization mapping the influence of the
681 plasma proteome on complex diseases. *Nat Genet* **52**, 1122–1131 (2020).
- 682 8. Ravindran, A. *et al.* Translatome profiling reveals Itih4 as a novel smooth muscle cell-specific
683 gene in atherosclerosis. *Cardiovascular Research* cvae028 (2024) doi:10.1093/cvr/cvae028.
- 684 9. Koprulu, M. *et al.* Proteogenomic links to human metabolic diseases. *Nat Metab* **5**, 516–528
685 (2023).
- 686 10. Yoshiji, S. *et al.* Proteome-wide Mendelian randomization implicates nephronectin as an
687 actionable mediator of the effect of obesity on COVID-19 severity. *Nat Metab* **5**, 248–264
688 (2023).

- 689 11. Peralta Cuasolo, Y. M. *et al.* The GTPase Rab21 is required for neuronal development
690 and migration in the cerebral cortex. *Journal of Neurochemistry* **166**, 790–808 (2023).
- 691 12. Köttgen, A. *et al.* Genome-wide association analyses identify 18 new loci associated with
692 serum urate concentrations. *Nat Genet* **45**, 145–154 (2013).
- 693 13. Lincoln, M. R. *et al.* Genetic mapping across autoimmune diseases reveals shared
694 associations and mechanisms. *Nat Genet* **56**, 838–845 (2024).
- 695 14. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia
696 MS/MRI Analysis Group. TNF neutralization in MS. *Neurology* **53**, 457–457 (1999).
- 697 15. Chen, G. *et al.* A UGT1A1 variant is associated with serum total bilirubin levels, which
698 are causal for hypertension in African-ancestry individuals. *npj Genom. Med.* **6**, 1–6 (2021).
- 699 16. Common CD36 SNPs reduce protein expression and may contribute to a protective
700 atherogenic profile | Human Molecular Genetics | Oxford Academic.
701 <https://academic.oup.com/hmg/article/20/1/193/2386020>.
- 702 17. Sniderman, A. D. *et al.* Apolipoprotein B Particles and Cardiovascular Disease: A
703 Narrative Review. *JAMA Cardiology* **4**, 1287–1295 (2019).
- 704 18. Ference, B. A. *et al.* Association of Triglyceride-Lowering LPL Variants and LDL-C–
705 Lowering LDLR Variants With Risk of Coronary Heart Disease. *JAMA* **321**, 364–373 (2019).
- 706 19. Ala-Korpela, M. The culprit is the carrier, not the loads: cholesterol, triglycerides and
707 apolipoprotein B in atherosclerosis and coronary heart disease. *International Journal of*
708 *Epidemiology* **48**, 1389–1392 (2019).
- 709 20. Finan, C. *et al.* The druggable genome and support for target identification and validation
710 in drug development. *Science Translational Medicine* **9**, eaag1166 (2017).
- 711 21. Wishart, D. S. *et al.* DrugBank: a comprehensive resource for in silico drug discovery
712 and exploration. *Nucleic Acids Research* **34**, D668–D672 (2006).

- 713 22. Smart-Halajko, M. C. *et al.* ANGPTL4 variants E40K and T266M are associated with
714 lower fasting triglyceride levels in Non-Hispanic White Americans from the Look AHEAD
715 Clinical Trial. *BMC Medical Genetics* **12**, 89 (2011).
- 716 23. Gagnon, E., Bourgault, J., Gobeil, É., Thériault, S. & Arsenault, B. J. Impact of loss-of-
717 function in angiopoietin-like 4 on the human phenome. *Atherosclerosis* **393**, 117558 (2024).
- 718 24. Rosenson Robert S. *et al.* Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for
719 Mixed Hyperlipidemia. *New England Journal of Medicine* **0**,.
- 720 25. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics
721 identifies additional variants influencing complex traits. *Nat Genet* **44**, 369–375 (2012).
- 722 26. Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic
723 Association Studies Using Summary Statistics. *PLOS Genetics* **10**, e1004383 (2014).
- 724 27. Robinson, J. W. *et al.* An efficient and robust tool for colocalisation: Pair-wise
725 Conditional and Colocalisation (PWCoCo). 2022.08.08.503158 Preprint at
726 <https://doi.org/10.1101/2022.08.08.503158> (2022).
- 727 28. Zhang, W. *et al.* SharePro: an accurate and efficient genetic colocalization method
728 accounting for multiple causal signals. *Bioinformatics* **40**, btae295 (2024).
- 729